Search Results
196 results
Your search is now limited to «Cystic Fibrosis» expert search.
European Respiratory Journal 01/17/2019 04:44
The epidemiology and natural history of cystic fibrosis (CF) is changing. Predicted median survival has increased over the past five decades, from less than 12 to more than 45 years in most Western countries, along with an estimated increase of the number of patients: by 20% in children and by 75% in adults, over the period 2010 to 2025 [1]. The number of adults (age ≥18 years) with CF is already larger than the number of children [2, 3]. This is a consequence of improvements in drug therapies and in the management of patients delivered by multidisciplinary teams in specialised CF centres, resulting in prolonged survival; this will be even more pronounced in the future, thanks to the introduction of new CFTR modulators acting on the dysfunc.
More from European Respiratory Journal:
BioNewsFeeds 01/16/2019 11:00
A baby born with cystic fibrosis (CF) today can now expect to live a median 44 years, says Preston W. Campbell, MD, president and CEO of the Cystic Fibrosis Foundation (CFF.
More from BioNewsFeeds: 01/14/2019 08:49
There are currently no large, multicenter prospective clinical trials examining management of constipation or other gastrointestinal (GI) symptoms in people with cystic fibrosis (CF.
More from
FeedNavigator 01/11/2019 07:20
Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis.
More from FeedNavigator: 01/09/2019 11:29
Scientists are working to correct a genetic defect in cystic fibrosis patients by having them inhale RNA.
More from
Cochrane Collaboration 01/08/2019 06:03
Evidence suggests that ivacaftor is an effective treatment for people (over six years of age) with cystic fibrosis and the G551D mutation, but not for those with the F508del or R117H mutations.
More from Cochrane Collaboration:
GlobeNewswire 01/03/2019 07:30
The Phase 1/2 clinical trial of MRT5005 for the treatment of CF is being conducted in collaboration with the Cystic Fibrosis Foundation Therapeutics Development Network.
More from GlobeNewswire:
Benzinga 12/26/2018 11:50
While Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s triple therapies may make modulator therapy available for nearly 90 percent of those with a CF mutation, modulators of the cystic fibrosis transmembrane conductance regulator are unlikely to fully reverse the structural damage in CF patients, the analyst said.
More from Benzinga:
Girl with cystic fibrosis is at the top of the national 'super urgent' list for a lung transplant.
More from Mail on Sunday (United Kingdom):
Respiratory Care 12/21/2018 09:33
The utility of using functional tests to evaluate longitudinal changes in muscle function and its association with clinical outcomes should be examined in cystic fibrosis.
More from Respiratory Care: 12/21/2018 02:39
We know that early detection can have significant benefits for people living with cystic fibrosis," said Dr. John Wallenburg, chief scientific officer at Cystic Fibrosis Canada.
More from
pharmaphorum 12/20/2018 08:02
Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.
More from pharmaphorum:
Business Wire 12/19/2018 12:04
If accepted by the SMC for use on the NHS in Scotland, eligible patients with cystic fibrosis (CF) in Scotland could have access to these precision medicines in 2019.
More from Business Wire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications